Search Results - "Fernández Clotet, A"

Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry by Iborra, M., Beltrán, B., Fernández‐Clotet, A., Gutiérrez, A., Antolín, B., Huguet, J.M., De Francisco, R., Merino, O., Carpio, D., García‐López, S., Mesonero, F., Navarro, P., Ferreiro‐Iglesias, R., Carbajo, A.Y., Rivero, M., Gisbert, J.P., Piñero‐Pérez, M.C., Monfort, D., Bujanda, L., García‐Sepulcre, M.F., Martín‐Cardona, A., Cañete, F., Taxonera, C., Domènech, E., Nos, P., Sierra‐Ausín, M., Ferrer‐Rosique, J.A., Martín‐Arranz, M.D., González‐Muñoza, C., Manceñido, N., Rodriguez‐Lago, I., Benítez, J.M., Forés‐Bosch, A., Navarro‐Llavat, M., Calafat, M., Madrigal‐Domínguez, R.E., Arroyo, M., Busquets, D., Lorente, R., Sainz‐Arnau, E., Hernández‐Camba, A., Morales‐Alvarado, V.J., Paredes, J.M., Van Domselaar, M., Hervás, D., Cañada‐Martínez, A., Castro‐Poceiro, J., Cameo‐Lorenzo, J., Fernández‐Salazar, L., Riestra, S., Casas‐Deza, D., Tosca, J., Barrio, J., García, M.J., Chaparro, M.

“…Summary Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real‐world,…”
Get full text

P276 Predictive value of changes in 3D volumetry in perianal fistulas in patients with Crohn’s disease under biologic therapy. A pilot study by Ordás Jiménez, I, Caballol, B, Saavedra, C, Fernández-Clotet, A, Masamunt, M, Ricart, E, Rimola, J

“…Abstract Background Changes in the 3D volumetry of perianal fistulas measured by magnetic resonance (MR) could be an imaging biomarker of interest. The…”
Get full text

P697 De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice by Arenas, A, Moreta, M J, Ordás, I, Fernández-Clotet, A, Caballol, B, Gallego, M, Vara, A, Barastegui, R, Giner, A, Prieto, C, Masamunt, M C, Ricart, E

“…Abstract Background Combination therapy with an immunomodulator (IMM) and an anti-TNF agent (specifically infliximab) is recommended in Crohn’s disease (CD)…”
Get full text

P026 Differential effects of tofacitinib on macrophage activation may contribute to lack of response in ulcerative colitis patients by Melón-Ardanaz, E, Veny, M, Corraliza, A M, Garrido-Trigo, A, Gudiño, V, Moro, M, Sanzo-Machuca, Á, Esteller, M, Masamunt, M C, Caballol, B, Ordás, I, Fernández-Clotet, A, Ricart, E, Panés, J, Salas, A

“…Abstract Background We previously showed that ulcerative colitis (UC) patients refractory to tofacitinib present an increase in the activation and the…”
Get full text

DOP05 Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients by Melón-Ardanaz, E, Veny, M, Corraliza, A M, Garrido-Trigo, A, Esteller, M, Rodrigo, M, Verstockt, B, Vermeire, S, Masamunt, M C, Giner, Á, Ordás, I, Fernández-Clotet, A, Ricart, E, Panés, J, Salas, A

“…Abstract Background Tofacitinib is an oral JAK1 and JAK3 inhibitor approved for the treatment of moderate to severe ulcerative colitis (UC). The aim of this…”
Get full text

Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU by Mesonero, F., Zabana, Y., Fernández-Clotet, A., Solá, A., Caballol, B., Leo-Carnerero, E., García, M.J., Bertoletti, F., Bastida, G., Suris, G., Casis, B., Ferreiro-Iglesias, R., Calafat, M., Jiménez, I., Miranda-Bautista, J., Lamuela, L.J., Fajardo, I., Torrealba, L., Nájera, R., Sáiz-Chumillas, R.M., González-Partida, I., Vicuña, M., García-Morales, N., Gutiérrez, A., López-García, A., Benítez, J.M., Rubín de Célix, C., Tejido, C., Brunet, E., Hernandez-Camba, A., Suárez, C., Rodríguez-Lago, I., Piqueras, M., Castaño, A., Ramos, L., Sobrino, A., Rodríguez-Grau, M.C., Elosua, A., Montoro, M., Baltar, R., Huguet, J.M., Hermida, B., Caballero-Mateos, A., Sánchez-Guillén, L., Bouhmidi, A., Pajares, R., Baston-Rey, I., López-Sanromán, A., Albillos, A., Barreiro-de Acosta, M.

“…Inflammatory pouch disorders exhibit a heterogeneous clinical spectrum and therapeutic requirements have not been properly studied. This retrospective,…”
Get full text

Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease by Rodríguez‐Lago, Iago, Castro‐Poceiro, Jesús, Fernández‐Clotet, Agnès, Mesonero, Francisco, López‐Sanromán, Antonio, López‐García, Alicia, Márquez, Lucía, Clos‐Parals, Ariadna, Cañete, Fiorella, Vicuña, Miren, Nantes, Óscar, Merino, Olga, Matallana, Virginia, Gordillo, Jordi, Elorza, Ainara, Vicente, Raquel, Casanova, María José, Ferreiro‐Iglesias, Rocío, Pérez‐Galindo, Pablo, Benítez, José Manuel, Taxonera, Carlos, García, María José, Martín, Eduardo, Aguirre, Urko, Gisbert, Javier P., Rodríguez‐Lago, I., Elorza, A., Castro‐Poceiro, J., Fernández‐Clotet, A., Mesonero, F., López‐Sanromán, A., López‐García, A., Márquez, L., Clos‐Parals, A., Cañete, F., Vicuña, M., Nantes, O., Merino, O., Matallana, V., Gordillo, J., Vicente, R., Casanova, M. J., Gisbert, J. P., Ferreiro‐Iglesias, R., Pérez‐Galindo, P., Manuel Benítez, J., Taxonera, C., García, M. J., Martín, E., Aguirre, U., Calafat, M., Muñoz, F., Miquel‐Cusachs, J. O., Sáinz, E.

“…Summary Background Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but…”
Get full text

DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry by Chaparro, M, García Donday, M, Núñez Ortiz, A, Calviño Suarez, C, Rubio Iturria, S, Sánchez Azofra, M, Calvo Moya, M, Pérez-Martínez, I, Fernández-Clotet, A, Alfambra, E, Marín Pedrosa, S, Diz-Lois Palomares, M T, Hernandez, V, Ruiz-Cerulla, A, Casanova, M J, Rivero, M, Huguet, J M, Vicente Lidón, R, Árias García, L, Guerra, I, Hervías Cruz, D, Gutiérrez Casbas, A, Bejarano, A, Camargo Camero, R, Rodríguez-Lago, I, Aguas, M, De Jorge Turrión, M Á, Masedo Gonzalez, Á, López Serrano, P, Valldosera Gomis, G, Ceballos, D, Bujanda, L, Molina Arriero, G, Vega Villaamil, P, Van Domselaar, M, Boscá Watts, M M, Lucendo, A J, Zúñiga de Mora-Figueroa, B, Busquets, D, Gisbert, J P

“…Abstract Background IBD remission is key for pregnancy outcomes. Previous studies have suggested a disease recurrence risk of approximately 30% in patients in…”
Get full text

P822 Therapeutic Management And Risk Of Colectomy In Patients With Acute Severe Ulcerative Colitis And Previous Exposure To Anti-Tnf Drugs. A Cohort Study Of Geteccu by Mesonero Gismero, F, López-García, A, Miranda-Bautista, J, Rubín de Célix, C, Marín-Jiménez, I, Suárez, C, Martin-Cardona, A, Fuentes, E, Mínguez, A, Castaño, A, Roig, C, Fernández-Clotet, A, Gargallo-Puyuelo, C J, Álvarez Herrero, B, García, M J, Segarra-Ortega, J X, Rodríguez-Grau, M C, López Romero-Salazar, F, Olmella, I, Martín-Rodríguez, D, González Vivo, M, Ponferrada, Á, Baston-Rey, I, Benítez, J M, Reygosa, C, Lastiri González, E A, Delgado-Guillena, P G, Torrealba, L, Hernández-Camba, A, Bernal, L, Pinero, G, Brunet, E, Irabien, M, Marquès-Camí, M, Zabana, Y, Gutiérrez, A

“…Abstract Background There are few data regarding the management on acute severe ulcerative colitis (ASUC) flare in patients with previous anti-TNF exposure. We…”
Get full text

P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results by Giordano, A, Rovira, M, Barastegui, R, Marín, P, Martínez, N, Fernández-Aviles, F, Suárez-Lledó, M, Doménech, A, Ordás, I, Fernández-Clotet, A, Caballol, B, Gallego, M, Vara, A, Masamunt, M C, Giner, A, Corraliza, A M, Panés, J, Salas, A, Ricart, E

“…Abstract Background Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with refractory Crohn’s disease [CD]…”
Get full text

P676 Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children's psychomotor development: Insights from the DUMBO registry of GETECCU by Palomino Pérez, L M, Velasco Rodríguez-Belvís, M, Brenes Ruiz, Y, Leo-Carnerero, E, Calviño Suarez, C, Rivero, M, Calvo, M, Arroyo, M T, Fernández-Clotet, A, Pérez-Martínez, I, Masedo González, Á, Hernández, V, Ruiz-Cerulla, A, López Serrano, P, Vega, P, Rodríguez-Lago, I, Vicente Lidón, R, De Jorge, M Á, Guerra, I, Arias García, L, Molina Arriero, G, Hervías Cruz, D, Busquets, D, Gutiérrez Casbas, A, Van Domselaar, M, Valldosera Gomis, G, Vázquez Morón, J M, Piqueras Cano, M, Lucendo, A J, Martín Arranz, M D, Ramírez de la Piscina, P, Martínez Tirado, M D P, Robles Alonso, V, Marín Pedrosa, S, Camargo Camero, R, Armesto Gonzalez, E, García-Salido, A, Muñoz Codoceo, R, Gisbert, J P, Chaparro, M

“…Abstract Background Understanding the impact of in utero exposure to biologic medications in children is crucial to providing recommendations during pregnancy…”
Get full text

DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study by Chaparro, M, Hermida, S, Acosta, D, Fernández-Clotet, A, Barreiro-de Acosta, M, Hernández Martínez, Á, Arroyo, M, Bosca-Watts, M M, Diz-Lois Palomares, M T, Menchén, L, Martínez Cadilla, J, Leo-Carnerero, E, Muñoz Villafranca, C, Sierra-Ausín, M, González, Y, Riestra, S, Sendra Rumbeu, P, Cabello Tapia, M J, García de la Filia, I, Montil Miguel, E, Ceballos, D, Pajares Villarroya, R, Ramírez de la Piscina, P, Martín-Arranz, M D, Ramos, L, Ruiz-Cerulla, A, Teresa de Jesús, M P, San Miguel, E, Calvet, X, Huguet, J M, Keco-Huerga, A, Lorente Poyatos, R H, Muñoz, J F, Ponferrada, Á, Sicilia Aladrén, B, Delgado-Guillena, P, Gómez Delgado, E, Rancel-Medina, F J, Alonso-Galán, H, Gisbert, J P

“…Abstract Background Primary aim: To assess the durability of ustekinumab treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the…”
Get full text

P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study by Sanz Segura, P, Gomollón, F, García García, S, Vela, M, Fernández-Clotet, A, Muñoz, R, García de la Filia, I, García Prada, M, Ferrer Rosique, J A, García, M J, de Francisco, R, Arias, L, Barrio, J, Guerra, I, Ponferrada Diaz, A, Gisbert, J P, Carrillo-Palau, M, Calvet, X, Márquez-Mosquera, L, Gros, B, Cañete, F, Monfort, D, Madrigal, R E, Roncero, O, Laredo, V, Montoro, M, Muñoz, C, López-Cauce, B, Lorente, R, Fuentes, A, Vega, P, Martín, D, Nerín de la Puerta, J, Varela, P, Casas-Deza, D, Martínez, P, Pajares, R, Lucendo, A J, Domènech, E, García-López, S

“…Abstract Background Some patients with Inflammatory Bowel Disease (IBD) who are treated with anti-TNFα therapy develop a drug-induced psoriasis (IP) as an…”
Get full text

P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases by Chaparro, M, Acosta, D, Rodríguez, C, Mesonero, F, Vicuña, M, Barreiro-de Acosta, M, Fernández-Clotet, A, Hernández Martínez, Á, Arroyo, M, Vera, I, Ruiz-Cerulla, A, Sicilia, B, Cabello Tapia, M J, Muñoz Villafranca, C, Castro-Poceiro, J, Martínez Cadilla, J, Sierra-Ausín, M, Vázquez Morón, J M, Montil Miguel, E, Bermejo, F, Royo, V, Calafat, M, González-Muñoza, C, Leo Carnerero, E, Manceñido Marcos, N, Torrealba, L, Alonso-Galán, H, Benítez, J M, Ber Nieto, Y, Diz-Lois Palomares, M T, García, M J, Muñoz, J F, Armesto González, E M, Calvet, X, Hernández-Camba, A, Madrigal Domínguez, R E, Menchén, L, Pérez Calle, J L, Piqueras, M, Gisbert, J P

“…Abstract Background Main aim: To assess the durability of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short…”
Get full text

P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding by Chaparro, M, García Donday, M, Rubio, S, Calviño Suarez, C, Nuñez Ortiz, A, Figueira, M, Marín Pedrosa, S, Rivero, M, Fernández-Clotet, A, Madero, L, Diz-Lois Palomares, M T, Pérez-Martínez, I, Ruiz-Cerulla, A, Arroyo, M, Piqueras, M, Suarez Ferrer, C, Aguas, M, Calvo Moya, M, Guerra, I, López Serrano, P, Vázquez Morón, J M, Arias García, L, Casanova, M J, Huguet, J M, Valldosera Gomis, G, Zúñiga de Mora-Figueroa, B, Armesto, R, Martínez Montiel, P, Rodríguez-Lago, I, Sendra Rumbeu, P, Camargo Camero, R, Hervías Cruz, D, Molina Arriero, G, Barreiro-de Acosta, M, Acosta, D, Brenes, Y, Hermida, S, Parra, P, Garre, A, Gisbert, J P

“…Abstract Background Biological drugs used for IBD are detected in breast milk at a concentration below 10% of the maternal serum concentration and have…”
Get full text

P293 Prognosis of small intestinal ulcers (SIUs) on capsule endoscopy when magnetic resonance enterography is normal by González Suárez, B, Castro-Poceiro, J, Fernández-Clotet, A, Feurstein, J, Ricart, E, Falchuk, K, Ordás, I, Rodriguez, S, Pleskow, D, LLach, J, Panés, J, Moss, A

“…Abstract Background Small intestinal ulcers (SIUs) are often identified during capsule endoscopy (CE) in patients whose MR enterography (MRE) is normal during…”
Get full text

P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU by Chaparro, M, Donday, M G, Rubio, S, Nuñez, A, Calviño Suarez, C, Madero, L, Figueira, M, Rivero, M, Pérez Martínez, I, Diz-Lois Palomares, M T, Huguet, J M, Marín Pedrosa, S, Aguas, M, Arroyo, M, Ruiz-Cerulla, A, Vázquez Morón, J M, Fernández-Clotet, A, Guerra, I, López Serrano, P, Rodríguez-Lago, I, Arias García, L, Camargo Camero, R, Casanova, M J, Martínez Montiel, P, Sendra Rumbeu, P, Suarez Ferrer, C, Valldosera Gomis, G, Armesto, R, Bujanda, L, Calvo Moya, M, Hervías Cruz, D, Robles Alonso, V, de Jorge Turrión, M Á, Zúñiga de Mora-Figueroa, B, Molina Arriero, G, Acosta, D, Brenes, Y, Hermida, S, Parra, P, Gisbert, J P

“…Abstract Background Most of the drugs approved for the treatment of inflammatory bowel disease (IBD) seem to be of low risk during pregnancy. However,…”
Get full text

P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety by Chaparro, M, Acosta, D, Rodríguez, C, Vicuña, M, Mesonero, F, Barreiro-de Acosta, M, Fernández-Clotet, A, Hernández Martínez, Á, Arroyo, M T, Vera Mendoza, I, Sicilia, B, Muñoz Villafranca, C, Castro-Poceiro, J, Martínez Cadilla, J, Vázquez Morón, J M, Montil, E, Sierra-Ausín, M, Calafat, M, Leo Carnerero, E, Manceñido Marcos, N, Torrealba M, L, Alonso-Galán, H, Benítez, J M, Ber Nieto, Y, Cabello Tapia, M J, Diz-Lois Palomares, M T, García, M J, Armesto González, E M, Calvet Calvo, X, Piqueras, M, Dueñas Sadornil, C, Pérez Calle, J L, Botella, B, Martínez-Pérez, T D J, Ramos, L, Rodríguez-Grau, M C, Fernández Forcelledo, J L, Gutiérrez, A, Sesé Abizanda, E, Gisbert, J P

“…Abstract Background Main aim: To assess the retention rate of tofacitinib treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the…”
Get full text

P410 Safety of biological drugs for inflammatory bowel disease in elderly patients by Suarez Ferrer, C J, Mesonero, F, Caballol, B, Ballester, M P, Baston Rey, I, Castaño Garcia, A, Miranda Bautista, J, Saiz Chumillas, R, Benitez, J M, Sanchez Delgado, L, Lopez-Garcia, A, Rubin de Celix, C, Lopez Sanroma, A, Martin-Arranz, M D, Fernández-Clotet, A, Merino Murgui, V, Calviño Suárez, C, Florez, P, Lobato matilla, M E, Sicilia, B, Soto Escribano, P, Maroto Martin, C, Alonso Abreu, I, Melcarne, L, Plaza Santos, R, Marques Cami, M, Caballero Mateos, A, Gómez Díez, C, Calafat, M, Alonso Galan, H, Vega Villaamil, P, Castro Senosiain, B, Guerro Moya, A, Rodriguez Diaz, C Y, Spicakova, K, Manceñido Marcos, N, Molina, G, De Castro, L, Mañosa Ciria, M, Barreiro-De Acosta, M

“…Abstract Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of…”
Get full text

DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD) by García, M J, Rivero, M, Fernández-Clotet, A, de Francisco, R, Sicilia, B, Mesonero, F, de Castro, M L, Casanova, M J, Bertoletti, F, García Alonso, F J, López García, A, Julián, B, Calvet, X, Barreiro-de Acosta, M, Jara, L, Varela, P, Nuñez, A, Ricart, E, Riestra, S, Arias, L, Rodríguez, M, Arranz, L, Pajares, R, Mena, R, Calafat, M, Camo, P, Jiménez, L, Ponferrada, A, Madrigal, R E, Llao, J, Sesé, E, Almela, P, Codesido, L, de la Maza, S, Leal, C, Sánchez, E, Pineda Mariño, J R, Domènech, E, Chaparro, M, Gisbert, J P

“…Abstract Background Main aim: To evaluate the retention rate of ustekinumab compared to vedolizumab in Crohn’s disease patients who failed anti-TNF therapy in…”
Get full text